Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1JCW8)

• Drug Name: Xaliproden Drug Info
• Synonyms: Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine

Indication

Disease Entry	ICD 11	Status	REF
Juvenile idiopathic arthritis	FA24	Phase 3	[1]
Plaque psoriasis	EA90.0	Phase 3	[1]
Alzheimer disease	8A20	Discontinued in Phase 3	[2]
Lateral sclerosis	8B61	Discontinued in Phase 3	[2]
Peripheral sensory neuropathies	LD27.3	Discontinued in Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 128919
  ChEBI ID: CHEBI:48520
  CAS Number: CAS 135354-02-8
  TTD Drug ID: DM1JCW8

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[5]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[6]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[7]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[8]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[9]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[10]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[11]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[12]
Treximet	DMU54QB	Migraine	8A80	Approved	[13]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[14]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[15]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[16]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[17]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[18]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[18]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[19]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[20]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[21]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[22]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Antagonist	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001601)
• [3] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [4] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [7] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [8] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [9] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [10] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [11] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [12] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [13] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [15] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [16] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [17] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [18] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [19] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [20] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [21] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [22] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.